Advised on Sale of Company


Adria Dental Group (Provectus Capital Partners)

Dental group Croatia

Acquired Majority Control of Business Operations

Rident Grupa

Polyclinics for dental medicine, implantology and dental laboratory Croatia

Advised Rident Group on sale to Adria Dental Group


Provectus Capital Partners (PCP), an investment company focused on markets in Southeast Europe, has invested in Rident Group, a leading Croatian dental group focused on providing dental services to foreign patients. The acquisition was carried through the holding company ASEF ADRIA d.o.o. (Adria Dental Group), a central consolidating entity within the dental sector established by PCP.

Rident Group consists of two dental polyclinics with 38 state-of-the-art equipped dental offices and the largest dental laboratory in the region.

Unique Selling Points

-       Strong brand in the dental field in Italy and Croatia.

-       Equipped with state-of-the-art diagnostic and laboratory equipment.

-       Highly experienced staff.

-       Wide sales network.

-       Large base of satisfied and loyal customers.

The Investor

ASEF ADRIA d.o.o. (Adria Dental Group) is a holding company established by Provectus Capital Partners (PCP), serving as the central entity for the consolidation of the dental sector in Southeast Europe.

Provectus Capital Partners is an investment company focused on the markets of Southeast Europe, which as invested in Rident Group through ASEF Adriatic Structured Equity Fund, which has also supported the investments into dental polyclinics Arena and Salona Dental. 


IMAP SEE was the exclusive transaction advisor to the owners of Rident Group in finding a strategic partner for Polyclinics Rident, dental laboratory Ridental and companies Sano Dent and Florin.

For many years the IMAP team has been a valuable and reliable partner to the owners of Rident Group. They guided us in a professional manner and directed us in the process of finding a strategic partner, but at the same time we felt that we have become one team. Continuous care and encouragement and exceptional technical and analytical help during due diligence have been incredibly important.

Dr. Željko Miljanić and Nataša Rubeša